Blockchain Registration Transaction Record

Soligenix Hits Key Milestone in Cutaneous T-Cell Lymphoma Treatment Trial

Soligenix completes enrollment for Phase 3 FLASH2 study of HyBryte in cutaneous T-cell lymphoma, reporting 48% response rate exceeding expectations. Interim analysis scheduled for 2026.

This development represents a significant advancement for patients suffering from cutaneous T-cell lymphoma, a rare and often debilitating cancer that currently lacks optimal treatment options. The impressive 48% response rate far exceeds expectations and suggests HyBryte could become a valuable new therapeutic option for this underserved patient population. For the broader pharmaceutical landscape, Soligenix's success demonstrates the viability of photodynamic therapy approaches and highlights the importance of continued investment in rare disease treatments. The company's progress also validates their specialized focus on addressing unmet medical needs, potentially paving the way for additional innovations in their pipeline targeting other inflammatory conditions and infectious diseases.